Effect of the drug indomethacin in the treatment of COVID-19 patients
Not Applicable
Completed
- Conditions
- COVID-19 (SARS-CoV-2 infection)Infections and Infestations
- Registration Number
- ISRCTN11970082
- Lead Sponsor
- Indian Institute of Technology Madras
- Brief Summary
2020 non-peer-reviewed results in preprint https://doi.org/10.1101/2020.12.14.20245266 (added 17/03/2021)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
1. Age 21 to 90 years
2. RT-PCR positive
3. Hospitalised patients
4. The case criteria for the study: LFT and KFT normal
Exclusion Criteria
1. Hypersensitivity/allergy to drug
2. Gastritis
3. Recent heart attack
4. Severe asthma
5. Acute kidney Injury
6. Patients on immunosuppressants
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patients deteriorating to severe disease measured using the WHO Ordinal Scale for Clinical Improvement every day during the treatment and after the treatment on the sixth day
- Secondary Outcome Measures
Name Time Method <br> 1. Kidney function measured using urea and creatinine before the start of the treatment and after the treatment on the sixth day<br> 2. Liver function measured using SGOT and SGPT before the start of the treatment and after the treatment on the sixth day<br> 3. Inflammation measured using C-reactive protein before the start of the treatment and after the treatment on the sixth day<br>